

1 *satuRn*:

2 Scalable Analysis of differential Transcript Usage  
3 for bulk and single-cell RNA-sequencing applications  
4

5 Jeroen Gilis<sup>1,2,6</sup>, Kristoffer Vitting-Seerup<sup>3,4</sup>, Koen Van den Berge<sup>1,5,6,7,8</sup> and Lieven Clement<sup>1,6,7,8</sup>

6 1. Department of Applied Mathematics, Computer Science & Statistics, Ghent University, Belgium.

7 2. Data Mining and Modeling for Biomedicine, VIB Center for Inflammation Research, Ghent, Belgium.

8 3. Department of Biology, The Bioinformatics Centre, University of Copenhagen

9 4. Biotech Research and Innovation Centre (BRIC), University of Copenhagen

10 5. Department of Statistics, University of California, Berkeley, CA, USA

11 6. Bioinformatics Institute Ghent, Ghent University, Ghent, Belgium.

12 7. These authors contributed equally.

13 8. Corresponding authors: [koen.vandenberge@ugent.be](mailto:koen.vandenberge@ugent.be); [lieven.clement@ugent.be](mailto:lieven.clement@ugent.be).

14 Abstract


15  
16 Alternative splicing produces multiple functional transcripts from a single gene. Dysregulation of  
17 splicing is known to be associated with disease and as a hallmark of cancer. Existing tools for  
18 differential transcript usage (DTU) analysis either lack in performance, cannot account for complex  
19 experimental designs or do not scale to massive scRNA-seq data. We introduce *satuRn*, a fast and  
20 flexible quasi-binomial generalized linear modelling framework that is on par with the best performing  
21 DTU methods from the bulk RNA-seq realm, while providing good false discovery rate control,  
22 addressing complex experimental designs and scaling to scRNA-seq applications.

23 Introduction

24  
25 Studying differential expression (DE) is one of the key tasks in the downstream analysis of RNA-seq  
26 data. Typically, DE analyses identify expression changes on the gene level. However, the widespread  
27 adoption of expression quantification through pseudo-alignment<sup>1,2</sup>, which enables fast and accurate  
28 quantification of expression at the transcript level, has effectively paved the way for transcript-level  
29 analyses. Here, we specifically address differential transcript usage (DTU) analysis, one type of  
30 transcript-level analysis that studies the change in relative usage of transcripts/isoforms within the  
31 same gene. DTU analysis holds great potential: previous research has shown that most multi-exon  
32 human genes are subject to alternative splicing and can thus produce a variety of functionally different  
33 isoforms from the same genomic locus<sup>3-5</sup>. The dysregulation of this splicing process has been reported  
34 extensively as a cause for disease<sup>6-9</sup>, including several neurological diseases such as frontotemporal  
35 dementia, Parkinsonism and spinal muscular atrophy, and is a well-known hallmark of cancer<sup>10</sup>.

36  
37 In this context, full-length single-cell RNA-Seq (scRNA-seq) technologies such as Smart-Seq2<sup>11</sup> and  
38 Smart-Seq3<sup>12</sup> hold the promise to further increase the resolution of DTU analysis from bulk RNA-seq  
39 data towards the single-cell level, where differences in transcript usage are expected to occur naturally  
40 between cell types. However, only a few bespoke DTU methods have been developed for scRNA-seq  
41 data and they lack biological interpretation. Indeed, methods specifically developed for scRNA-seq  
42 data are either restricted to exon/event level<sup>13,14</sup> analysis (e.g. pinpointing exons involved in splicing  
43 events), or they can only pinpoint DTU genes without unveiling the actual transcripts that are  
44 involved<sup>15</sup>. Interestingly, many DTU methods for bulk RNA-seq do provide inference at the transcript  
45 level and their performance has already been extensively profiled in benchmark studies<sup>16-18</sup>. Based on  
46 a subset of the simulated RNA-seq dataset from Love *et al.*<sup>18</sup> (see Methods), we show the performance  
47 of six DTU tools; DEXSeq<sup>19</sup>, DoubleExpSeq<sup>20</sup>, DRIMSeq<sup>21</sup>, edgeR diffSplice<sup>22</sup>, limma diffSplice<sup>23</sup> and

48 NBSplice<sup>24</sup> (Figure 1A). DEXSeq and DoubleExpSeq have a higher performance than the other methods.  
 49 In addition, we observe that most methods, and DRIMSeq in particular, fail to control the false  
 50 discovery rate (FDR) at its nominal level, which is in line with previous reports<sup>16–18</sup>.  
 51



52 **Figure 1: Performance and scalability evaluation of six DTU methods. A: Performance evaluation on the**  
 53 **simulated bulk RNA-Seq dataset from Love *et al.*<sup>18</sup>**. Each curve displays the performance of each method by  
 54 evaluating the sensitivity (TPR) with respect to the false discovery rate (FDR). The three circles on each curve  
 55 represent working points when the FDR level is set at nominal levels of 1%, 5% and 10%, respectively. The circles  
 56 are filled if the empirical FDR is equal or below the imposed FDR threshold. DEXSeq and DoubleExpSeq clearly  
 57 have the highest performances. Note that most methods, and DRIMSeq in particular, fail to control the FDR at  
 58 its nominal level. **B: Scalability with respect to the number of cells in a scRNA-Seq dataset.** While all other  
 59 methods scale linearly with an increasing number of cells, DEXSeq scales quadratically. As such, DEXSeq cannot  
 60 be used for the analysis of large bulk and scRNA-Seq datasets. For all sample sizes, the number of transcripts in  
 61 the datasets were set at 30.000. Note that NBSplice needed to be omitted from this analysis as it fails to converge  
 62 on datasets with a large proportion of zero counts (see below). **C: Scalability with respect to the number of**  
 63 **transcripts in a scRNA-Seq dataset.** While all other methods scale linearly with an increasing number of cells,  
 64 BANDITS scales quadratically. Moreover, BANDITS failed to run on our system for datasets with 7.500 transcripts  
 65 or more. As such, it had to be omitted from panels A and B. A performance and scalability evaluation of BANDITS  
 66 on datasets with an (artificial) lower number of transcripts is provided in supplementary Figures S1 and S3.  
 67

68 In order to assess DTU in single-cell applications, however, these bulk RNA-seq DTU tools should scale  
 69 to the large data volumes generated by full-length scRNA-seq platforms, which can profile the  
 70 transcriptome of several thousands of cells<sup>25–27</sup> in a single experiment. In Figure 1B, we evaluate the  
 71 required computational time in function of the number of sequenced libraries for a two-group DTU

72 analysis for 30,000 transcripts on a subset of the scRNA-seq dataset from Chen *et al.*<sup>28</sup>. In spite of its  
73 good performance, the popular tool DEXSeq already required more than five hours to analyze two  
74 groups of 32 cells and clearly does not scale to large bulk nor scRNA-seq datasets.

75  
76 In addition, DTU methods should allow for the analysis of datasets with large numbers of (unique)  
77 transcripts. The number of transcripts that are typically assessed depends on the coverage of the RNA-  
78 seq experiment and the adopted filtering criteria in the data analysis workflow. As the coverage of  
79 RNA-seq experiments has increased rapidly over the past few years and can be expected to continue  
80 expanding, scalability towards large numbers of transcripts will be essential to enable a transcriptome-  
81 wide view on the isoform usage changes. In Figure 1C, we perform a DTU analysis across a range of  
82 transcripts in a two-group comparison with 16 cells each, using the dataset from Chen *et al.* Here, we  
83 observed that the DTU tool BANDITS<sup>29</sup> scales particularly poorly to large numbers of transcripts. More  
84 specifically, BANDITS did not complete the DTU analysis on the dataset with 7.500 transcripts within  
85 137 hours on our system (see Methods); therefore, larger analyses were omitted. As such, BANDITS  
86 had to be omitted from the analyses shown in Figures 1A and 1B. For a performance and scalability  
87 evaluation of BANDITS on datasets with an (artificial) lower number of transcripts, we refer to Figures  
88 S1 and S3.

89  
90 Besides scalability, several other issues arise when porting bulk RNA-seq DTU tools towards scRNA-  
91 seq applications. Indeed, modeling scRNA-seq data often requires multifactorial designs, for instance  
92 when comparing expression levels across multiple cell types between multiple treatment groups.  
93 Accounting for multiple covariates, however, is not implemented in BANDITS, NBSplice and  
94 DoubleExpSeq, jeopardizing their utility for (sc-)RNA-seq DTU analysis. Another issue arises with the  
95 large numbers of zero counts in scRNA-seq data, which seems to be particularly problematic for  
96 NBSplice that fails to converge if the gene-level count of any of the samples or cells is zero. As such,  
97 NBSplice could not be evaluated in Figures 1B and 1C.

98  
99 Altogether, many of the existing DTU analysis tools are not well suited to analyze large bulk RNA-seq  
100 and full-length scRNA-seq datasets, leaving the great potential of these data largely unexploited. In  
101 light of these shortcomings we developed *saturn*, which is an acronym for Scalable Analysis of  
102 differential Transcript Usage for RNA-seq data, a novel method for DTU analysis that (i) is highly  
103 performant, (ii) provides a good control of the false discovery rate (FDR) (iii) scales seamlessly to the  
104 large data volumes of contemporary (sc-)RNA-seq datasets, (iv) allows for modelling complex  
105 experimental designs, (v) can deal with realistic proportions of zero counts and (vi) provides direct  
106 inference on the biologically relevant transcript level. In brief, *saturn* adopts a quasi-binomial (QB)  
107 generalized linear model (GLM) framework. *saturn* provides direct inference on DTU by modelling the  
108 relative usage of a transcript, in comparison to other transcripts from the same gene, between groups  
109 of interest. To stabilize the estimation of the overdispersion parameter of the QB model, we borrow  
110 strength across transcripts by building upon the empirical Bayes methodology as introduced by Smyth  
111 *et al.*<sup>23</sup>. In order to control the number of false positive findings, an empirical null distribution is used  
112 to obtain the p-values, which are corrected for multiple testing with the FDR method of Benjamini and  
113 Hochberg<sup>30</sup>. Our method is implemented in an R package available at  
114 <https://github.com/statOmics/saturn> and will be submitted to the Bioconductor project.

## 115 Results

116  
117 We first evaluate the performance of our novel DTU method, *saturn*, on publicly available simulated  
118 and real bulk RNA-seq data, as well as on real scRNA-seq data. In general, we found that the  
119 performance of *saturn* was at least on par with the performances of the best tools from the literature.  
120 In addition, our method controls the FDR closer to the nominal level, on average. Second, we show  
121 that *saturn* scales towards the large data volumes generated by contemporary bulk and single-cell


122 RNA-seq experiments, allowing for a transcriptome-wide analysis of datasets consisting of several  
123 thousands of cells, in only a few minutes. Finally, we analyze a large full-length scRNA-seq case study  
124 dataset, where we obtain highly relevant biological results on isoform-level changes between cell  
125 types that would have remained obscured in a canonical differential gene expression (DGE) analysis.  
126

## 127 Performance on simulated bulk RNA-seq datasets

128  
129 To evaluate the performance of satuRn, we adopt three simulated bulk RNA-seq datasets from  
130 previous publications. Dataset 1 was obtained from Love *et al.*<sup>18</sup> and contains two groups of twelve  
131 samples each, which we subsample without replacement to evaluate 3vs3, 6vs6 and 10vs10 two-  
132 group comparisons. Datasets 2 and 3 are the *Drosophila melanogaster* and *Homo sapiens* simulation  
133 studies from Van den Berge *et al.*<sup>31</sup> and Sonesson *et al.*<sup>17</sup>, which both contain two groups of five samples  
134 each. In brief, all datasets were constructed by generating sequencing reads based on parameters that  
135 are estimated from real bulk RNA-seq data. DTU between groups of samples was artificially introduced  
136 in the data, prior to the quantification of expression using either Salmon<sup>2</sup> (dataset 1) or kallisto<sup>1</sup>  
137 (dataset 2 and 3). Notably, there are some methodological differences between the simulation  
138 framework of dataset 1 and that of datasets 2 and 3 with respect to the read generation and the  
139 simulation of DTU signal (see Methods). In terms of transcript filtering, we adopt two different  
140 strategies as implemented by edgeR<sup>32</sup> and DRIMSeq<sup>21</sup>, which correspond to a lenient and more  
141 stringent filtering, respectively (see Methods).  
142

143 The result of the performance evaluation of satuRn with respect to other DTU methods on the three  
144 simulated bulk datasets is displayed in Figure 2. Figure 2A shows the average performance over three  
145 6 versus 6 subsamples for dataset 1, after filtering with edgeR. Figures 2B and 2C display the  
146 performance on datasets 2 and 3 after edgeR filtering, respectively. In all three datasets, satuRn  
147 outperforms NBSplice, edgeR diffsplice and limma diffsplice. Intriguingly, the performance of  
148 DRIMSeq varies strongly between the three datasets. This discrepancy may be explained by the  
149 different strategies for generating reads and introducing DTU between dataset 1, and, datasets 2 and  
150 3 (see methods). We furthermore find the performance of satuRn is on par with the best performing  
151 tools from the literature, DEXSeq and DoubleExpSeq. In addition, both satuRn and DoubleExpSeq  
152 provide a stringent control of the FDR, while DEXSeq and DRIMSeq are often too liberal, as reported  
153 previously<sup>18</sup>.  
154

155 We also evaluated the effects of sample size and different filtering criteria on the performance of the  
156 different DTU methods (see Figures S2, S3, S4 and S5). Neither sample size nor filtering criterion had  
157 a profound impact on the ranking of the performances of the different DTU methods; satuRn, DEXSeq  
158 and DoubleExpSeq remain the best performing methods overall. In addition, we studied the impact of  
159 using either raw count estimates or normalized abundance estimates (scaledTPM, see Methods) as  
160 input data for the DTU algorithms. We observed a slightly higher performance in all datasets when  
161 providing raw abundance estimates, except for Dataset 1 from Love *et al.*<sup>18</sup>. All performance  
162 evaluations in the body of this publication therefore were generated with raw count estimates as input  
163 data, except for Figure 2, panel A. For a full overview on the effects of sample size, filtering criteria  
164 and data input type, we refer to supplementary figures S2-S9.  
165  
166  
167  
168




169 **Figure 2: Performance evaluation of *saturn* on three simulated bulk RNA-Seq datasets.** Each curve visualizes  
 170 the performance of each method by displaying the sensitivity of the method (TPR) with respect to the false  
 171 discovery rate (FDR). The three circles on each curve represent working points when the FDR level is set at  
 172 nominal levels of 1%, 5% and 10%, respectively. The circles are filled if the empirical FDR is equal or below the  
 173 imposed FDR threshold. The performance of *saturn* is on par with the best tools from the literature, DEXSeq  
 174 and DoubleExpSeq, for all datasets. In addition, our method consistently controls the FDR close to its imposed  
 175 nominal FDR threshold.  
 176

### 177 Performance on a real bulk RNA-seq dataset

178  
 179 While simulation studies are common for evaluating the performance of DE analysis methods, there  
 180 is currently no consensus on the simulation strategy that best mimics real (sc)RNA-seq data. In  
 181 addition, simulation frameworks typically generate data according to parametric assumptions on the  
 182 data-generating mechanism, thus potentially favoring DE methods that adopt similar distributional  
 183 assumptions in their statistical model<sup>33</sup>. An alternative procedure is to non-parametrically modify a  
 184 real dataset. Here, we obtained different subsamples from the large bulk RNA-seq dataset available  
 185 from the Genotype-Tissue Expression (GTEx) consortium<sup>34</sup>, generating 9 datasets in total, i.e. 3 repeats  
 186 for each of 3 sample sizes; *5 versus 5*, *20 versus 20* and *50 versus 50* samples. We then artificially  
 187 introduced DTU in these data by swapping transcript usages between groups of samples (see Methods  
 188 for details). Again, we adopt two different filtering strategies as implemented by edgeR<sup>32</sup> and  
 189 DRIMSeq<sup>21</sup> (see Methods).  
 190

191 The results of the performance evaluation of *saturn* on the real bulk datasets upon edgeR filtering is  
 192 displayed in Figure 3. In agreement with the results obtained from the simulated bulk RNA-seq study,  
 193 we observe that the performance of *saturn* is on par with DEXSeq and DoubleExpSeq. Again, *saturn*  
 194 provides a conservative FDR control. While the FDR control of DoubleExpSeq is good overall, it appears

195 to become too liberal with increasing sample size. In this evaluation, DRIMSeq performs poorly, in  
 196 contrast to simulated bulk RNA-seq datasets 2 and 3, but in line with the performance evaluation on  
 197 the simulated bulk RNA-seq dataset 1. Note that DEXSeq, DRIMSeq and NBSplice were omitted from  
 198 the analysis of the largest dataset (*50 versus 50* samples), as these methods do not scale to such large  
 199 datasets (Figure 1). Adopting the DRIMSeq-based filtering did not have a qualitative impact on the  
 200 performance (Figure S6).



201 **Figure 3: Performance evaluation of satuRn on a real bulk RNA-Seq dataset.** Each curve visualizes the  
 202 performance of each method by displaying the sensitivity of the method (TPR) with respect to the false discovery  
 203 rate (FDR). The three circles on each curve represent working points when the FDR level is set at nominal levels  
 204 of 1%, 5% and 10%, respectively. The circles are filled if the empirical FDR is equal or below the imposed FDR  
 205 threshold. The performance of satuRn is on par with the best tools from the literature, DEXSeq and  
 206 DoubleExpSeq. In addition, satuRn consistently controls the FDR close to its imposed nominal FDR threshold,  
 207 while DoubleExpSeq becomes more liberal with increasing sample sizes. Note that DEXSeq, DRIMSeq and  
 208 NBSplice were omitted from the larger comparison, as these methods do not scale to large datasets (Figure1).

### 209 Performance on real single-cell data


210

211 Finally, we evaluate the performance of satuRn on single-cell RNA-seq data. As with the real bulk  
 212 analysis, the single-cell datasets were generated by subsetting from three different real scRNA-seq  
 213 datasets<sup>25,28,35</sup> (see Methods). Again, we subsampled three repeats of different sample sizes, artificially  
 214 introduced DTU with the swapping strategy and applied either the edgeR- or DRIMSeq-based filtering  
 215 criterium (see Methods for details).

216

217 By subsampling the Chen et al.<sup>28</sup> dataset, we generated three repeats of two sample sizes, i.e. *20*  
 218 *versus 20* and *50 versus 50 cells*. The results of the performance evaluation of satuRn on this dataset  
 219 upon edgeR filtering is displayed in Figure 4. The performance of satuRn is slightly better than that of  
 220 the best tool from the literature, DoubleExpSeq. As compared to the evaluations on bulk data, we  
 221 observe a performance drop for DEXSeq relative to satuRn and DoubleExpSeq. This, in combination  
 222 with its poor scalability (Figure 1), greatly compromises the use of DEXSeq for the analysis of scRNA-  
 223 seq data. satuRn again provides a stringent control of the FDR, while the inference of DoubleExpSeq  
 224 is too liberal, again becoming more problematic for larger sample sizes. Adopting the DRIMSeq filter  
 225 did not have a qualitative impact on the performances (Figure S7). The results of the performance  
 226 evaluations on the other two scRNA-seq datasets<sup>25,35</sup> are in strong agreement with the results  
 227 displayed here, with satuRn performing at least on par with DoubleExpSeq and satuRn additionally  
 228 controlling the FDR around the nominal level (Figures S8 and S9).

229 Notably we found that the theoretical null distribution of the test statistics from satuRn failed to  
 230 provide good FDR control in single-cell analyses (Figure S10). To obtain proper p-values with satuRn in  
 231 single-cell applications, we therefore estimate the null distribution of the test statistic empirically (see  
 232 Methods, satuRn paragraph). Note, that the use of the empirical null distribution in our bulk RNA-seq  
 233 benchmarks does not affect the results because no deviations of the theoretical null distribution  
 234 occur. However, the empirical null resulted in much improved FDR control in scRNA-seq datasets  
 235 (Figure S10). We therefore adopt the empirical null estimation as the default setting in satuRn. As  
 236 such, all satuRn results in this publication are relying on the empirical null strategy. As a final remark,  
 237 we likewise attempted to improve the FDR control of DoubleExpSeq. However, in all analyses with  
 238 DoubleExpSeq we observed a large spike of p-values equal to 1, which poses a problem when  
 239 estimating the empirical null distribution (Figure S11). Therefore, this strategy could not be used to  
 240 improve the FDR control of DoubleExpSeq.



241 **Figure 4: Performance evaluation of satuRn on a real scRNA-Seq dataset.** Each curve visualizes the performance  
 242 of each method by displaying the sensitivity of the method (TPR) with respect to the false discovery rate (FDR).  
 243 The three circles on each curve represent working points when the FDR level is set at nominal levels of 1%, 5%  
 244 and 10%, respectively. The circles are filled if the empirical FDR is equal or below the imposed FDR threshold.  
 245 The performance of satuRn is on par with the best tools from the literature, DEXSeq and DoubleExpSeq. In  
 246 addition, our method provides a stringent control of the FDR, while DoubleExpSeq becomes more liberal with  
 247 increasing sample sizes (see also Figure S6). Note that DEXSeq and DRIMSeq were omitted from the two largest  
 248 comparisons, as these methods do not scale to large datasets (Figure1). NBSplice was omitted from all  
 249 comparisons, as it does not converge on datasets with many zeros, such as scRNA-Seq datasets.


251  
 252 **Scalability benchmark**

253  
 254 We performed a computational benchmark of satuRn to investigate its scalability with respect to the  
 255 number of samples/cells and the number of transcripts in an RNA-seq dataset. All scalability  
 256 benchmarks were run on a single core of a Linux machine with an Intel(R) Xeon(R) CPU E5-2420 v2  
 257 (2.20GHz, Speed: 2200 MHz) processor and 30GB RAM. The results are displayed in Figure 5.

258  
 259 Figure 5A displays the scalability with respect to the number of cells in the dataset, while keeping the  
 260 number of transcripts in the dataset fixed at 30.000. From the left panel, it is clear that DRIMSeq and  
 261 especially DEXSeq scale very poorly with the number of cells in the dataset, which was already shown  
 262 in Figure 1B. In the right panel, we focus on the four remaining methods. satuRn scales linearly with  
 263 increasing numbers of cells, with a slope comparable to limma diffsplice. As such, satuRn is able to  
 264 perform a DTU analysis on a dataset with two groups of 256 cells each and 30.000 transcripts in less

265 than three minutes. Note that BANDITS<sup>29</sup> was not included in this benchmark, as it does not scale to  
 266 datasets with this many transcripts. For a performance and scalability evaluation of BANDITS on  
 267 datasets with a lower number of transcripts, we refer to Figure S1. NBSplice was also omitted as it fails  
 268 to converge on datasets with a large proportion of zero counts.

270 Figure 5B shows the scalability with respect to the number of transcripts in the dataset, while keeping  
 271 the number of cells in the dataset fixed to two groups of 16 cells. As shown in Figure 1C, BANDITS,  
 272 DEXSeq and DRIMSeq scale poorly to datasets with many transcripts. From the right panel, satuRn  
 273 scales linearly with increasing numbers of transcripts, albeit with a steeper slope than edgeR diffsplice,  
 274 DoubleExpSeq and limma diffsplice. Note, that the scalability of DTU analyses can be improved  
 275 through parallelization, if this is allowed by the underlying algorithm. Parallel execution is  
 276 implemented in satuRn and in all methods from the literature that were discussed in this manuscript,  
 277 except for DoubleExpSeq and NBSplice.



278  
 279 **Figure 5: Scalability evaluation of satuRn on scRNA-Seq data. A: Runtime with respect to the number of cells**  
 280 **in a scRNA-Seq dataset. Left panel:** it is clear that DRIMSeq and especially DEXSeq scale very poorly with the  
 281 **number of cells in the dataset. Right panel:** Detailed plot of the remaining methods. satuRn scales linearly with  
 282 **increasing numbers of cells, with a slope that is comparable to that of limma diffsplice. As such, satuRn is able**  
 283 **to perform a DTU analysis on a dataset with two groups of 256 cells each and 30.000 transcripts in less than**  
 284 **three minutes. For all sample sizes, the number of transcripts in the datasets were set at 30.000. Note that**  
 285 **NBSplice was not included in this analysis as it fails to converge on datasets with a large proportion of zero**  
 286 **counts. B: Runtime with respect to the number of transcripts in a scRNA-Seq dataset. Left panel:** DEXSeq,



287 DRIMSeq and especially BANDITS scale poorly to the number of transcripts in the dataset. **Right panel:** Detailed  
288 plot of the remaining methods. satuRn scales linearly with increasing numbers of transcripts, but with a steeper  
289 slope than edgeR diffsplice, DoubleExpSeq and limma diffsplice. The number of cells in the dataset was set fixed  
290 to two groups of 16 cells. All scalability benchmarks were run on a single core.

291

292 Altogether, we find that while several methods for DTU analysis exist, none are optimally suited for  
293 analyzing single-cell datasets. DRIMSeq, NBSplice, edgeR diffsplice and limma diffsplice have a much  
294 lower overall performance in our benchmarks. DEXSeq does not scale to large datasets. Finally,  
295 DoubleExpSeq does not support experimental designs that require an analysis with multiple additive  
296 effects, e.g. randomized complete block designs and designs where batch-effect correction is  
297 required, which are essential for many practical scRNA-Seq analysis settings<sup>36</sup>. In addition, it fails to  
298 control the FDR at the desired level, especially with increasing sample sizes.

299

## 300 Case study

301

302 We use satuRn to perform a DTU analysis on a subset of the single-cell (SMART-seq<sup>211</sup>) RNA-seq  
303 dataset from Tasic *et al.*<sup>35</sup>. In addition, we analyze the same dataset with DoubleExpSeq and limma  
304 diffsplice, which are the only other DTU methods that scale to large scRNA-seq datasets and have a  
305 reasonable performance in our benchmarks. In the original publication, the authors studied  
306 differential gene expression between cell types originating from two areas at distant poles of the  
307 mouse neocortex; the primary visual cortical area (VISp), which processes sensory information with  
308 millisecond timescale dynamics<sup>37-39</sup> and the anterior lateral motor cortex (ALM), which displays slower  
309 dynamics related to short-term memory, deliberation, decision-making and planning<sup>40,41</sup>. Based on  
310 marker genes, Tasic *et al.*<sup>35</sup> assigned all of the 23.822 cells from the scRNA-seq dataset to one of three  
311 cell classes; glutamatergic (excitatory) neurons, GABAergic (inhibitory) neurons or non-neuronal cells.  
312 The authors then further classified the neuronal cells into several subclasses based on their dominant  
313 layer of dissection and projection patterns (through a retrograde labelling experiment). Finally, these  
314 subclasses are further classified into cell types based on the expression of specific marker genes.

315

## 316 DGE analysis with edgeR

317

318 In their original DGE analysis, Tasic *et al.*<sup>35</sup> obtained the largest number of differentially expressed  
319 genes between the cell types originating from the ALM and VISp regions of the glutamatergic L5 IT  
320 subclass (2.739 cells in total), where L5 refers to layer-of-dissection 5 and IT refers to the  
321 intratelencephalic projection type. Here, we first perform a DGE analysis with an edgeR-based  
322 workflow (see Methods) on the same comparisons between L5 IT cell types that were assessed by  
323 Tasic *et al.* Table 1 shows the number of differentially expressed genes between the groups of interest  
324 in column 4.

325

## 326 DTU analysis with satuRn

327

328 Next, we perform a DTU analysis for the same cell types using satuRn. In column 5 of Table 1, we  
329 display the number of differentially used transcripts for each comparison. We also show the number  
330 of unique genes in which we find evidence for changes in usage of at least one transcript (column 6).  
331 While the number of differentially used transcripts is lower than the number of differentially  
332 expressed genes in each of the contrasts, we did identify differentially used transcripts in all contrasts  
333 of interest. Most interestingly, we observe that the overlap between the differentially expressed  
334 genes and the genes in which we found evidence for DTU is very limited (Table 1, column 7). This  
335 shows that the information obtained from our DTU analyses are orthogonal to the results from the  
336 canonical DGE analyses, which has been reported previously for simulated bulk data<sup>18</sup>.

337

338 **Table 1: Number of differentially expressed genes and differentially used transcripts in eight comparisons**  
 339 **between cell types.** The first three columns indicate the comparisons between ALM (column 2) and VISp (column  
 340 3) cell types, respectively. Column 4 indicates the number of differentially expressed genes as identified with an  
 341 edgeR analysis. Column 5 displays the number of transcripts that satuRn flagged as differentially used. Column  
 342 6 shows the number of unique genes in which satuRn finds evidence of differential usage of at least one  
 343 transcript. Column 7 displays the absolute number of genes that overlap between columns 4 and 6.  
 344

Comparison	Cell type 1 (ALM)	Cell type 2 (VISp)	DGE	DTU Tx	DTU Gene	Overlap
1	Cpa6 Gpr88	Batf3	203	24	15	1
2	Cbln4 Fezf2	Col27a1	281	92	53	3
3	Cpa6 Gpr88	Col6a1 Fezf2	154	7	5	0
4	Gkn1 Pcdh19	Col6a1 Fezf2	231	33	22	1
5	Lypd1 Gpr88	Hsd11b1 Endou	331	118	69	4
6	Tnc	Hsd11b1 Endou	595	193	112	10
7	Tmem163 Dmrtb1	Hsd11b1 Endou	471	90	53	7
8	Tmem163 Arhgap25	Whrn Tox2	197	63	40	1

345

### 346 *Gene set enrichment analysis*

347


348 We perform a gene set enrichment analysis (GSEA) on the three comparisons with most DE genes and  
 349 most genes with evidence for DTU (comparisons 5, 6 and 7). Similar gene ontology categories are  
 350 returned for the set of DGE genes and the set of DTU genes, with many of the enriched processes  
 351 being biologically relevant in the context of this case study. Enriched gene sets include the gene  
 352 ontology classes, synapse, neuron projection, synaptic signaling and cell projection organization. This  
 353 shows that the complementary information brought by the DTU analysis is indeed biologically  
 354 relevant. For an extensive overview of the GSEA of the set of DGE genes and genes with evidence of  
 355 DTU in comparisons 5, 6 and 7, we refer to supplementary table 1.

356

### 357 *satuRn identifies biologically relevant DTU transcripts*

358

359 To display the utility of satuRn for identifying and visualizing DTU transcripts in scRNA-seq datasets,  
 360 we focus on comparison #6 of the DTU analysis and discuss the gene P2X Purinoceptor 4 or P2rx4  
 361 (Ensembl ID ENSMUSG00000029470), a gene which is part of a family of purinergic receptors that  
 362 have been implicated in functions such as learning, memory and sleep. In the DGE analysis, no  
 363 evidence for differential expression of P2rx4 was found at the gene level (FDR-adjusted p-value = 1).  
 364 By contrast, in our DTU analysis the transcripts of P2rx4 displayed the highest statistical evidence for  
 365 differential usage within the set of transcripts that could be assigned to the ontology class 'neuron  
 366 projection'<sup>42</sup>. The mean usage of transcript ENSMUST00000081554 is estimated to be 28.9% in Tnc  
 367 cells and 75.9% in Hsd11b1 Endou cells (FDR-adjusted p-value = 1.22E-13). For transcript  
 368 ENSMUST000000195963, the transcript usage changes from 58.2% in Tnc cells and 16.6% in Hsd11b1  
 369 Endou cells (FDR-adjusted p-value = 1.79E-10). For the third transcript of P2rx4 that was assessed in  
 370 our DTU analysis, ENSMUST000000132062, we found no statistical evidence for DTU (FDR-adjusted p-  
 371 value = 0.534). In Figure 6, we show the output for the visualization of the transcript usages for P2rx4  
 372 as obtained from satuRn. Interestingly, the majority transcript in the Tnc cell type,  
 373 ENSMUST000000195963, is not protein coding<sup>43</sup>. By contrast, the majority transcript in the Hsd11b1  
 374 Endou cell type, ENSMUST00000081554, is coding for the P2X purinoceptor protein (UniProt ID  
 375 Q9Z256). As such, the changes in transcript usage between both cell types represent actual biological  
 376 differences in the functionality of the gene products, which may be relevant to the process of neuron  
 377 projection. This functional difference would have remained obscured when only performing a  
 378 canonical DGE analysis.




379  
 380 **Figure 6: Differential transcript usage in the P2rx4 gene.** Each panel shows transcript usage or gene expression  
 381 across cells of the Tnc and Hsd11b1 cell types. For the transcript-level figures, the size of each datapoint is  
 382 weighted according to the total expression of the gene in that cell, i.e. the gene counts per cell. The yellow  
 383 diamonds indicate the estimated mean usage of a transcript for each cell type, as estimated by satuRn. The cyan  
 384 and dark green diamonds indicate mean and median gene expression levels per cell type, respectively. The two  
 385 top panels display the transcript usage across cells of the Tnc and Hsd11b1 Endou cell types of transcripts  
 386 ENSMUST0000081554 and ENSMUST00000195963, respectively. The proportion of usage of the former  
 387 transcript is clearly higher in Hsd11b1 Endou cells, while the latter transcripts is most abundant in Tnc cells. For  
 388 the third transcript, ENSMUST00000132062 (bottom left panel) there is no evidence for differential usage  
 389 between both cell types. In addition, there is no evidence for differential expression of P2rx4 on the gene level  
 390 (bottom right panel). DTU and DGE significance levels are indicated in the figure headers.  
 391

392 **Comparison to limma diffsplice**

393  
 394 We also analyzed the case study dataset with limma diffsplice<sup>23</sup>. When running limma diffsplice with  
 395 default settings, a large number of DTU transcripts was returned (Figure S12) and we observe that the  
 396 p-values were shifted towards smaller values (Figures S13 and S14). Therefore, we adopted the same  
 397 empirical null strategy as implemented in satuRn to post-process the results. While this dramatically  
 398 decreased the number of significant DTU transcripts, limma diffsplice still identified more transcripts  
 399 (i.e. true or false positives) than our method. However, when we inspected the transcripts that were

400 highly ranked in the top DTU list of limma diffsplice but lowly ranked in our top list, we found that  
 401 most of these transcripts either originate from genes that are lowly expressed, or they are transcripts  
 402 with a large fraction of zero counts (i.e. zero expression in a large percentage of cells). Limma diffsplice  
 403 thus claims differential usage more often for transcripts that only contain little information for  
 404 assessing DTU. This is depicted in Figure 7.



405 **Figure 7: Global comparison between DTU transcripts uniquely identified by satuRn, uniquely identified by**  
 406 **limma diffsplice or by both methods. Left panel:** Boxplots on the average gene-level count for the DTU genes  
 407 identified by the respective methods. Transcripts uniquely identified by satuRn originate from genes that have  
 408 a much higher gene-level count (averaged over cells) as compared to transcripts uniquely identified by limma  
 409 diffsplice. Note that the y-axis is displayed on a log10 scale. **Right panel:** Violin plots indicating the fraction of  
 410 cells in which the transcripts are expressed. Transcripts uniquely identified by satuRn are expressed, on average,  
 411 in a much larger fraction of the cells. Conversely, transcripts identified as DTU uniquely by limma diffsplice often  
 412 have no expression in a large fraction of the cells. The dark green diamond indicates the median fraction of cells  
 413 in which the DTU transcripts are expressed.


414  
 415 This behavior can be expected. Limma diffsplice tests for DTU by comparing the log-fold change in  
 416 expression of transcript  $t$  with the average log-fold change in the expression of all transcripts  
 417 belonging to the same gene as transcript  $t$ . As such, limma diffsplice does not incorporate any  
 418 information on the absolute gene expression levels. In contrast, our quasi-binomial GLM framework  
 419 models the log-odds of drawing a particular transcript  $t$  from the pool of transcripts in the  
 420 corresponding gene. As a consequence, transcripts belonging to lowly expressed genes are correctly  
 421 considered less informative in satuRn and are thus less likely to be picked up. For example, in Figure  
 422 8A, we show that while our method estimates a mean usage of 7% in Tnc cells and 26% in Hsd11b1  
 423 Endou cells (indicated by the gold diamond), the transcript is not identified as differentially used, given  
 424 the low abundance of the corresponding gene and the highly variable single-cell level observations.

425  
 426 Conversely, by looking at the transcripts that were highly ranked in our DTU list but lowly ranked in  
 427 the top list of limma, we observe that our model is more likely to capture small changes in transcript  
 428 usage that are stable across all cells and belong to genes that are highly expressed. An example of  
 429 such a transcript is shown in Figure 8B. satuRn estimates a mean usage of 3% in Tnc cells and 6% in  
 430 Hsd11b1 Endou cells. While this is only a minor change in transcript usage, satuRn still identifies this  
 431 transcript as differentially used because the gene is highly expressed and the small change in usage is  
 432 supported by a large number of cells. In case such small differences in usage are not considered  
 433 biologically meaningful, it is possible to set a threshold on the minimal desired difference. Finally, by  
 434 not taking into account gene abundances, limma is more influenced by outlying observations that have  
 435 a low gene-level abundance (Figure 8C). Indeed, DTU claims by limma are driven by differences in raw  
 436 mean usages of transcripts. In Figure 8C, the raw mean usage of the transcript is 77% in Tnc cells and  
 437 45% in Hsd11b1 Endou cells, as indicated by the cyan diamonds. By contrast, the mean usage estimate

438 by satuRn, which takes into account that the Hsd11b1 Endou cells expressing the transcript at 0%  
 439 usage have low gene-level count, is 83% for Tnc cells and 75% for Hsd11b1 Endou cells, as indicated  
 440 by the gold diamonds.

441

442 We therefore argue that, given the above observations, the transcripts identified by satuRn should be  
 443 considered more reliable, as they generally originate from genes containing more information for  
 444 assessing DTU.



445

446 **Figure 8: Three examples displaying DTU transcripts that are uniquely identified by satuRn or limma diffsplice.**


447 Each panel shows transcript usage across cells of the Tnc and Hsd11b1 cell types. The size of each datapoint is  
 448 weighted according to the total expression of the corresponding gene in that cell, i.e. the total gene count per  
 449 cell. The yellow diamonds indicate the estimated mean usage of a transcript for each cell type, as estimated by  
 450 satuRn. The cyan diamonds indicate the mean transcript expression levels per cell type. The header of each  
 451 panel indicates the FDR-adjusted p-value and the rank of the DTU finding in the top lists by limma diffsplice and  
 452 satuRn analyses. **Panel A:** Transcript uniquely identified as differentially used by limma diffsplice. The DTU claim  
 453 by limma is driven by the difference in mean transcript usage between cell types. Given the low abundance of  
 454 the corresponding gene and the highly dispersed single-cell level observations, satuRn doesn't identify the  
 455 transcript as differentially used. **Panel B:** Transcript uniquely identified as differentially used by satuRn. Even  
 456 though the mean difference in transcript usage between cell types is estimated to be 3%, satuRn claims  
 457 significance given that the difference is stably supported by many cells with high gene-level expression levels.  
 458 **Panel C:** Transcript uniquely identified as differentially used by limma diffsplice. The DTU claim by limma is driven

459 by the raw mean difference in transcript usage between cell types. In contrast, satuRn takes into account that  
 460 the Hsd11b1 Endou cells expressing the transcript at 0% usage have low gene-level count. The size of the dots  
 461 (which represent individual cells) is weighted according to the total expression of the gene in that cell, i.e. the  
 462 total gene count per cell. The yellow diamonds indicate the estimated mean usage of a transcript for each cell  
 463 type, as estimated by satuRn. The cyan diamonds indicate the raw mean transcript usage levels per cell type.  
 464

#### 465 Comparison to DoubleExpSeq

466  
 467 We additionally analyzed the dataset by Tasic *et al.* with DoubleExpSeq<sup>20</sup>. DoubleExpSeq identified a  
 468 large number of DTU transcripts in all eight comparisons between cell types, ranging from 335 to 4580  
 469 DTU transcripts (Figure S12). This is consistent with our performance benchmarks, which already  
 470 suggested that DoubleExpSeq becomes overly liberal in single-cell datasets with a large number of  
 471 cells (Figures 4, S7, S8 and S9). We therefore expect many of these transcripts to correspond to false  
 472 positives. Furthermore, this is reflected in the pathological distribution of p-values obtained by  
 473 DoubleExpSeq, where p-values have a tendency to be small and therefore the analysis too liberal  
 474 (Figure S15). Furthermore, as discussed in the benchmark studies, we could not adopt the empirical  
 475 null strategy to improve the FDR control of DoubleExpSeq. Again, a large number of p-values equal 1  
 476 poses a problem for estimating the empirical null distribution (Figure S16).  
 477

478 While the results of DoubleExpSeq are likely to be overly liberal, the ranking of the transcripts (based  
 479 on the p-values of the DTU analysis) might still be reasonable. In Figure 9, we observe a large overlap  
 480 between the top 200 transcripts identified by satuRn in comparison #6 of the case study and the top  
 481 200 transcripts of DoubleExpSeq in that comparison. This overlap is considerably smaller with a limma  
 482 diffsplice analysis.



**Figure 9: Venn diagram displaying the degree of overlap of the top 200 transcripts in comparison #6 of the case study in three DTU analysis tools.** We observe that in the set of the top 200 transcripts identified by satuRn, 149 transcripts overlap with the top 200 list from DoubleExpSeq. In the top 200 list of limma diffsplice, 108 transcripts are present that were not in the top lists of satuRn or DoubleExpSeq.

483  
 484 Finally, we note that while DoubleExpSeq could still be used in this case study given the simple factorial  
 485 design (using a single factor to assign each cell to a cell type), DoubleExpSeq cannot be used in  
 486 multifactorial designs, for instance to compare expression levels across multiple cell types between  
 487 multiple samples or treatment groups.

488

489

490

491

492

## 493 Discussion

494

495 In this manuscript, we have proposed satuRn, a new software tool for DTU analysis. satuRn adopts a  
496 quasi-binomial GLM framework and obtains direct inference on DTU by modelling the relative usage  
497 of a transcript, in comparison to other transcripts from the same gene, between conditions of interest.  
498 We evaluated the performance of satuRn with respect to 7 other DTU methods on three simulated  
499 bulk RNA-seq datasets, a real bulk RNA-seq dataset and three real scRNA-seq datasets. These  
500 benchmarks underscored the strong performance of satuRn, as well as its ability to control the FDR  
501 close to the nominal level. In addition, we showed that satuRn scales seamlessly to the large data  
502 volumes that are produced in contemporary (sc-)RNA-seq experiments. Furthermore, given the  
503 underlying GLM framework, our method can handle complex experimental designs that are  
504 commonplace in scRNA-seq experiments. Finally, satuRn can extract biologically relevant information  
505 from a large scRNA-seq dataset that would have remained obscured in a canonical DGE analysis.

506

507 Since most sequencing reads map to multiple transcripts, quantification tools such as Salmon or  
508 kallisto only provide an estimate of the expected number of fragments originating from each  
509 transcript. Incorporating quantification uncertainty has recently been shown to improve results in  
510 differential expression analysis of single-cell RNA-seq datasets<sup>44</sup>. Currently, satuRn and all other DTU  
511 methods discussed in this manuscript, except for BANDITS<sup>29</sup>, neglect the uncertainty on this  
512 abundance estimate. BANDITS models the abundance uncertainty, however, it had a markedly lower  
513 performance than our method in our benchmark evaluation (Figure S1).

514

515 One challenge common to all DTU methods is that the power to detect differentially used transcripts  
516 depends strongly on the quality of the scRNA-seq dataset. This becomes clear when comparing the  
517 performances for the three different scRNA-seq benchmarks in this manuscript. The performances on  
518 the Darmanis<sup>25</sup> dataset (Figure S9) are markedly lower than the performances on the other two  
519 datasets (Figures 4 and S8). A closer inspection of the Darmanis dataset showed that, after filtering,  
520 the transcript-level counts matrix contains a much larger percentage of zero counts than the other  
521 datasets. We also more frequently observed the scenario where the expression level of a gene could  
522 be attributed to a single isoform. This effectively causes the transcript usage to appear binary, with  
523 either 0% or 100% usages of a certain transcript. We argue that while this may reflect the true  
524 underlying biology, for instance through the process of transcriptional bursting<sup>45,46</sup>, it is more likely to  
525 be a technical artefact as a consequence of more shallow sequencing, given the lower percentage of  
526 binary usage profiles in the Chen and Tasic datasets. The supposedly binary expression of transcripts  
527 due to coverage-dependent bias and the use of more stringent filtering criteria to reduce this bias has  
528 already been comprehensively reported by Najjar *et al.*<sup>47</sup>.

529

530 We conclude with the following recommendations for DTU analysis from an applied perspective. In  
531 case of small bulk RNA-seq datasets, satuRn, DEXSeq and DoubleExpSeq can be used interchangeably.  
532 In case of datasets with more complex designs that require the DTU model to incorporate additional  
533 covariates, e.g. batch effects, DoubleExpSeq cannot be used. For single-cell datasets, using DEXSeq  
534 will become infeasible in terms of scalability and DoubleExpSeq may give overly liberal results. As such,  
535 we recommend satuRn for performing DTU analyses in large bulk and single-cell RNA-seq datasets.

536

537

538

539

540

541

## 542 Methods

543

### 544 satuRn model

545 As input, satuRn requires a matrix of transcript-level expression counts, which may be obtained either  
546 through pseudo-alignment using kallisto<sup>1</sup> or salmon<sup>2</sup>, or by classical alignment-based tools followed  
547 by transcript-level quantification (e.g. STAR<sup>48,49</sup> and RSEM<sup>50</sup>). Let  $Y_{gti}$  denote the observed expression  
548 value for a given transcript  $t = 1, \dots, T_g$  of gene  $g = 1, \dots, G$  in cell or sample  $i = 1, \dots, n$ . The total  
549 expression of gene  $g$  in sample  $i$  can then be expressed as

$$550 \quad Y_{g.i} = \sum_{t \in T_g} Y_{gti} \quad (1),$$

551 i.e. by taking the sum of expression values for all  $T_g$  transcripts belonging to gene  $g$  in sample  $i$ . The  
552 usage of transcript  $t$  in sample or cell  $i$  can then be estimated as

$$553 \quad U_{gti} = \frac{Y_{gti}}{Y_{g.i}} \quad (2).$$

554 Next, we adopt a quasi-binomial (QB) generalized linear modelling (GLM) strategy to model DTU. As  
555 opposed to canonical maximum likelihood models, this quasi-likelihood modelling strategy only  
556 requires the specification of the first two moments of the response distribution, i.e. the mean and the  
557 variance. We define the mean of the QB model as

$$558 \quad \left\{ \begin{array}{l} E[U_{gti} | \mathbf{X}_i, Y_{g.i}] = \pi_{gti} \\ \log\left(\frac{\pi_{gti}}{1 - \pi_{gti}}\right) = \eta_{gti} \\ \eta_{gti} = \mathbf{X}_i^T \boldsymbol{\beta}_{gt} \end{array} \right. \quad (3)$$

561

562 In this notation,  $\pi_{gti}$  is the expected probability of observing transcript  $t$  within the pool of transcripts  
563 ( $1, \dots, T_g$ ) belonging to gene  $g$  in sample  $i$  and, as such, corresponds to its expected usage for that  
564 sample. We model  $\pi_{gti}$  using a logit link *function*, where  $\boldsymbol{\beta}_t$  is a  $p \times 1$  column vector of regression  
565 parameters modeling the association between the average usage and the covariates for transcript  $t$ .  
566 Finally,  $\mathbf{X}_i^T$  is a row in the  $n \times p$  design matrix  $\mathbf{X}$  that corresponds with the covariate pattern of sample  
567  $i$ , with  $p$  the number of parameters of the mean model, i.e. the length of vector  $\boldsymbol{\beta}_t$ .

568

569 The variance of the QB model can be described as

$$570 \quad \text{Var}[U_{gti} | \mathbf{X}_i, Y_{g.i}] = \frac{\pi_{gti}(1 - \pi_{gti})}{Y_{g.i}} \phi_{gt} \quad (4)$$

571 with  $Y_{g.i} \pi_{gti}(1 - \pi_{gti})$  the canonical variance of the binomial distribution and  $\phi_{gt}$  a transcript-specific  
572 overdispersion parameter to describe additional variance in the data with respect to the binomial  
573 variance. We adopt the empirical Bayes procedure from Smyth *et al.*<sup>23</sup>, as implemented in the  
574 *squeezeVar* function of the *limma* Bioconductor R package, to stabilize the estimates of  $\phi_{gt}$  by  
575 borrowing information across transcripts, which is adopted in the default edgeR quasi-likelihood  
576 workflow for bulk RNA-seq data<sup>22</sup> Note that stabilizing the dispersion estimation is particularly useful  
577 in datasets with a small sample size.



578 Taken together, the quasi-binomial thus allows us to model the log-odds of drawing a particular  
 579 transcript  $t$  from the pool of transcripts in the corresponding gene  $g$  across samples. The intercept also  
 580 has an interpretation of a log-odds and the remaining mean model parameters are log-odds ratios,  
 581 which may thus be interpreted in terms of differential transcript usage. We adopt t-tests that are  
 582 computed based on the log-odds ratio estimates of the QB model and the posterior variance, as  
 583 obtained from the empirical Bayes procedure. P-values are computed assuming a t-distribution under  
 584 the null hypothesis with posterior degrees of freedom calculated as the sum of the residual degrees  
 585 of freedom and the prior degrees of freedom from the empirical Bayes procedure.

586 For bulk analyses, the implementation of satuRn as described above provides a high performance and  
 587 a good control of the FDR. However, for single-cell datasets we observed that our inference is too  
 588 liberal (Figure S10), which could suggest that the theoretical null, the t-distribution, is no longer valid.  
 589 Indeed, in large-scale inference settings, failure of the theoretical null distribution is often observed.  
 590 Efron<sup>52</sup> (Chapter 6) describes four reasons why the theoretical null distribution may fail; failed  
 591 mathematical assumptions, correlation across features (transcript expression), correlation across  
 592 subjects (samples or cells), and unobserved confounders in observational studies. To avoid these  
 593 issues, Efron proposes to exploit the massive parallel data structure of omics datasets to empirically  
 594 estimate the null distribution of the test statistics<sup>53</sup>. To this end, Efron converts the test statistic to z-  
 595 scores, which should follow a standard normal distribution under the theoretical null, and then  
 596 proposes to approximate the empirical null distribution with a normal distribution with unknown  
 597 mean ( $\mu^*$ ) and standard deviation ( $\sigma^*$ ), which can be estimated by maximum likelihood on a subset of  
 598 the test statistics near zero.

599 As such, we first convert the two-sided p-values to z-scores according to

$$600 \quad z_{gt} = \Phi^{-1}\left(\frac{p_{gt}}{2}\right) * \text{sign}(S), \quad (5)$$

601 with  $\Phi$  the cumulative distribution function for the standard normal distribution,  $p_{gt}$  the original two-  
 602 sided p-value indicating the statistical significance of differential usage of transcript  $t$  from gene  $g$   
 603 between the conditions of interest,  $\text{sign}(S)$  the sign of the t-test statistic  $S$  and  $z_{gt}$  the resulting z-score.  
 604 Next, we adopt the maximum likelihood procedure, implemented in the *locfdr* function of the *locfdr*  
 605 R package from CRAN<sup>54</sup>, to estimate the mean  $\mu^*$  and standard deviation  $\sigma^*$  of the empirical null  
 606 distribution. Based on these estimates, we recompute the z-scores and corresponding p-values as  
 607 follows

$$608 \quad z_{gt}^* = \frac{(z_{gt} - \mu^*)}{\sigma^*} \quad (7)$$

$$609 \quad p_{gt}^* = 2 * \Phi(-\text{abs}(z_{gt}^*)) \quad (8).$$

610 Finally, the resulting (empirical) p-values are corrected for multiple testing with the FDR method of  
 611 Benjamini and Hochberg<sup>30</sup>. As opposed to the original p-values that were calculated based on the  
 612 theoretical null distribution for the t-statistics, we found that this procedure allows for a better FDR  
 613 control in single-cell applications.

## 614 DTU tools literature

615

616 Below we provide a brief description of each of the DTU methods from the literature that were  
 617 included in the performance benchmarks of this paper. For more details, we refer to the respective  
 618 original publications. Note that all methods were run with the current default settings.

619

## 620 DEXSeq

621

622 DEXSeq<sup>19</sup> (R package version 1.32.0) takes as input a transcript-level expression matrix  $Y_{ti}$ , with  $T$   
623 transcripts (rows) and  $n$  samples or cells (columns). Next, a matrix of complementary counts  $C_{ti}$  is  
624 calculated, which defines how many reads map to any of the other transcripts of the same gene as  
625 respective transcript  $t$  in cell  $i$ . DEXSeq then augments the original expression matrix  $Y_{ti}$  by  
626 concatenating it with the complementary counts  $C_{ti}$ , hence doubling the number of columns of the  
627 original count matrix. A negative binomial generalized linear model (GLM) is fitted to each transcript  
628 in the augmented count matrix as follows

629

630

631

632

$$\left\{ \begin{array}{l} \{Y_{ti}, C_{ti}\} \sim NB(\mu_{ti}, \phi_t) \\ \log(\mu_{ti}) \sim \eta_{ti} \\ \eta_{ti} \sim \mathbf{X}_i^T \boldsymbol{\beta}_t. \end{array} \right.$$

633 In the specification of the GLM,  $\mathbf{X}_i^T$  corresponds to row  $i$  of design matrix  $\mathbf{X}$ , which defines a covariate  
634 pattern that (i) links the transcript-level count matrix to the complementary counts through sample-  
635 level intercepts, and (ii) specifies the design of the experiment. Inference on DTU is obtained by testing  
636 an interaction effect that assesses if the log fold change between transcript  $t$  and all other transcripts  
637 in its corresponding gene changes between the conditions of interest (e.g. treatment) with a likelihood  
638 ratio test. It is important to note that the estimation of sample-level intercepts is required because of  
639 the concatenation of the two count matrices. As a consequence, DEXSeq scales quadratically with the  
640 number of samples or cells in the data. The lack of scalability is thus inherent to the parametrization  
641 of DEXSeq, putting a severe burden on the utility of DEXSeq for DTU analysis in large datasets, as  
642 displayed in Figure 1.

643

## 644 DoubleExpSeq

645

646 DoubleExpSeq<sup>20</sup> (R package version 1.1) assumes a double binomial distribution for each transcript.  
647 The double binomial distribution is a member of the double exponential family of distributions  
648 described by Efron<sup>55</sup>, which are extensions of one-parameter exponential family distributions that  
649 allow for a more flexible variance structure through introduction of an additional dispersion  
650 parameter. DoubleExpSeq adopts a bespoke empirical Bayes procedure for computing shrinkage  
651 estimates of the dispersion parameter of the double binomial distribution. The double binomial  
652 models the log-odds of drawing a particular transcript  $t$  from the pool of transcripts in the  
653 corresponding gene  $g$  across samples. The intercept thus has an interpretation of a log-odds and the  
654 remaining mean model parameter(s) are log-odds ratios, which may thus be interpreted in terms of  
655 differential transcript usage. The significance of the mean model parameter(s) are tested using a  
656 likelihood ratio test. Importantly, the current implementation of DoubleExpSeq does not allow for  
657 modeling multifactorial designs and cannot make use of parallel computing.

658

## 659 DRIMSeq

660

661 DRIMSeq<sup>21</sup> (R package version 1.14.0) assumes that the transcript-level expression counts marginally  
662 follow a Dirichlet multinomial distribution (DM), where the Dirichlet conjugate prior is used to account  
663 for overdispersion with respect to the multinomial distribution. The most important consequence of  
664 treating transcript expression as a realization of a multinomial distribution, is that the correlations  
665 between expression of transcripts derived from the same gene are directly accounted for. In the  
666 DRIMSeq framework, the total count for a gene is considered fixed, and the quantity of interest is the  
667 change in proportion of each transcript within a gene between groups of samples or cells. More

668 specifically, DRIMSeq uses a likelihood ratio test to determine if the transcript ratios of a gene, which  
669 are modelled by the multinomial, are different between conditions of interest.

670

#### 671 [Limma diffsplice](#)

672

673 Limma diffsplice (limma, R package version 3.42.2) is a built-in functionality described in the current  
674 user's guide of the limma Bioconductor R package<sup>23</sup>. Limma was originally devised for analyzing  
675 microarray data but can also be used for RNA-Seq data with the limma-voom method<sup>56</sup>. Limma-voom  
676 fits a linear model to the log-transformed (normalized) transcript-level count matrix, while adjusting  
677 for heteroskedasticity via weighted regression, where the observation weights are computed from the  
678 observed variance-mean relationship. Limma diffsplice then uses a series of t-tests to assess DTU at  
679 the transcript level by comparing the log-fold change in expression of transcript  $t$  with the average  
680 log-fold change in the expression of all transcripts belonging to the same gene as transcript  $t$ .

681

#### 682 [EdgeR diffsplice](#)

683

684 EdgeR diffsplice (edgeR, R package version 3.28.1) is a built-in functionality described in the vignettes  
685 of the edgeR Bioconductor R package, which was last revisited by Chen et al.<sup>22</sup>. The edgeR diffsplice  
686 function fits a negative binomial GLM for each transcript and tests for differential transcript usage by  
687 comparing the obtained log-fold changes for each respective transcript within a gene with the log-fold  
688 change of the entire gene. If the log-fold change for a certain transcript is significantly different from  
689 those of the other transcripts in the gene, it is flagged as differentially used. Note that the negative  
690 binomial GLMs can be fit using a canonical likelihood-based approach or using a quasi-likelihood. We  
691 adopted the likelihood-based approach as it consistently displayed higher performances (data not  
692 shown). In this setting, inference is obtained using a likelihood ratio test.

693

#### 694 [NBSplice](#)

695

696 NBSplice<sup>24</sup> (R package version 1.4.0) fits a negative binomial GLM for each transcript in the dataset. In  
697 contrast to e.g. DEXSeq, the mean transcript-level expression (i.e. the mean parameter of the negative  
698 binomial model) is taken as the product of the mean gene-level expression value and the observed  
699 percentual usage of the transcripts within its corresponding gene. The GLM framework of NBSplice is  
700 structured such that DTU between groups of interest can be tested using a likelihood ratio test, where  
701 the full model contains an isoform-condition interaction term that is omitted in the null model. Note  
702 that in our benchmarks the NB GLM estimation procedure of NBSplice fails to converge when there is  
703 a large fraction of zero counts in the data. As a consequence, NBSplice was omitted from the  
704 performance benchmarks on single-cell data and from the scalability benchmarks, as the latter also  
705 make use of single-cell data.

706

#### 707 [BANDITS](#)

708

709 BANDITS<sup>29</sup> (R package version 1.3.2) adopts a Bayesian hierarchical model with a Dirichlet-multinomial  
710 to explicitly model the sample-to-sample variability between biological replicates. In addition to the  
711 transcript-level count matrix, equivalence class counts are used as input to the BANDITS algorithm. As  
712 described by Bray et al.<sup>1</sup>, an equivalence class for a (transcriptomics) read is a multi-set of transcripts  
713 associated with that read. As such, an equivalence class represents the transcripts from which a read  
714 could have originated. BANDITS leverages the information conveyed by the equivalence class counts  
715 to model the uncertainty arising from reads mapping to multiple transcripts. In brief, the allocation of  
716 reads to transcripts is treated as a latent variable that is sampled jointly with the parameters of the  
717 Dirichlet-multinomial; sampling of these parameters is done with a Markov chain Monte Carlo

718 algorithm. As such, BANDITS allows for modeling the mean relative usage of each transcript within its  
719 corresponding gene across samples/cells, while accounting for quantification uncertainty. In addition,  
720 BANDITS also accounts for differences in transcript length. Finally, BANDITS tests for DTU (at the  
721 transcript level) by performing univariate Wald tests.

722

## 723 Filtering

724

725 We adopted two different strategies for filtering transcripts in each of the RNA-seq datasets in the  
726 performance benchmarks.

727

728 The first filtering strategy uses the *filterByExpr* function implemented in edgeR<sup>57</sup>. This filtering strategy  
729 only retains transcripts that have at least an expression level of *min.count* counts-per-million (CPM,  
730 calculated as the number of read counts divided by the total number of reads in the dataset and  
731 multiplied by one million) in at least  $n$  samples or cells. In addition, the sum of the CPM of the  
732 transcript across all cells or samples must be at least *min.total.count*. For the bulk RNA-seq datasets,  
733 we use the default settings (*min.count* = 10,  $n$  = min(10, 0.7\*sample size of the smallest group in the  
734 comparison) and *min.total.count* = 10). For the scRNA-seq datasets, the settings are adjusted to;  
735 *min.count* = 1 (as requiring a transcript to be expressed in all single-cells is a stringent criterium),  $n$  =  
736 0.5\*sample size of the smallest group in the comparison and *min.total.count* = 0. In addition, if only  
737 one transcript of a gene passes this filtering criterion, it is omitted from the analysis, as DTU analysis  
738 is meaningless when only one transcript is retained. As such, we specifically set the parameters to  
739 generate a very lenient filtering criterium.

740

741 The second filtering strategy uses the *dmFilter* function implemented in DRIMSeq<sup>21</sup>. This filter is more  
742 stringent and specifically designed for DTU analysis. The filtering process can be thought of as  
743 proceeding in three steps. Let  $n_s$  be the number of samples or cells in the smallest group. The first step  
744 requires the transcripts to have a count of at least 10 in at least  $n_s$  samples. The second filtering step  
745 requires the transcript to make up at least 10% of the total count of its corresponding gene in at least  
746  $n_s$  samples. The third filtering step removes all transcripts for which the corresponding gene has a  
747 count below 10 in any of the samples or cells in the dataset. Again, if only one transcript of a gene  
748 passes this filtering criterion, it is omitted from the analysis.

749

## 750 Bulk simulation study

751

752 To evaluate the performance of the different DTU analysis methods, we first adopt three simulated  
753 bulk RNA-seq datasets from previous publications: the simulated dataset from Love et al.<sup>18</sup> (dataset  
754 1) and both the *Drosophila melanogaster* (dataset 2) and *Homo sapiens* (dataset 3) simulation studies  
755 from Van den Berge et al.<sup>31</sup>. All three datasets were generated based on parameter values obtained  
756 from real RNA-seq samples, to mimic real RNA-seq data as close as possible.

757

758 Notably, there is a subtle difference in how DTU is introduced between the two simulation  
759 frameworks. For dataset 1, the origin of DTU is twofold: On the one hand, DTU was specifically  
760 introduced by swapping the transcript-per-million (TPM) abundances between two expressed  
761 isoforms. On the other hand, DTU was also obtained as a consequence of introducing DTE, where a  
762 single expressed isoform was induced to be differentially expressed at a certain log fold change, which  
763 leads to DTU if this transcript belongs to a gene expressing multiple isoforms. For datasets 2 and 3,  
764 there is only one source of DTU. The number of differentially used transcripts within a gene was  
765 sampled ranging from a minimum of 2 up to a random number drawn from a binomial distribution  
766 with size equal to the number of transcripts and success probability 1/3. DTU was introduced by  
767 swapping the TPM abundances between the differentially used transcripts. As such, the latter  
768 framework allows for differential usage of multiple transcripts of the same gene, which is not possible

769 with the framework used for generating dataset 1. Additionally, dataset 1 uses salmon<sup>2</sup> (version 1.1.0)  
770 for estimating transcript-level abundances, whereas datasets 2 and 3 were quantified with kallisto<sup>1</sup>  
771 (version 0.46.2).

772

### 773 Real bulk study

774

775 We evaluate the performance of the different DTU methods on real bulk RNA-seq data, by  
776 subsampling a homogeneous set of samples from the large bulk RNA-seq dataset available from the  
777 Genotype-Tissue Expression (GTEx) consortium<sup>34</sup> release version 8. Nine datasets were generated  
778 non-parametrically. More specifically, we first selected samples from adrenal gland tissue that were  
779 extracted with the RNA extraction method “RNA Extraction from Paxgene-derived Lysate Plate Based”.  
780 From the remaining samples we subsampled 9 datasets, comprising 3 repeats for each of 3 sample  
781 sizes; 5 versus 5, 20 versus 20 and 50 versus 50 samples. Next, DTU is artificially introduced with the  
782 swapping strategy that is described in the bulk simulation study paragraph of the Methods section of  
783 this paper. The GTEx data was quantified with RSEM<sup>50</sup> version 1.3.0.

784

### 785 Real single-cell study

786

787 We evaluate the performance of the different DTU methods on real scRNA-seq datasets. These scRNA-  
788 seq datasets were generated non-parametrically by subsampling a homogeneous set of cells from  
789 three real scRNA-seq datasets<sup>25,28,35</sup>, after which DTU is artificially introduced by the swapping strategy  
790 that is described in the bulk simulation study paragraph of the Methods section of this paper.

791

792 For the dataset of Chen *et al.*<sup>28</sup>, which was used to construct Figures 4 and S7, we selected a  
793 homogeneous population of cells by considering only the EpiStem cells of female mice, resulting in a  
794 dataset of 120 cells. From this homogeneous population of cells, we then subsampled 6 datasets,  
795 comprising 3 repeats for each of 2 sample sizes: 20 versus 20 and 50 versus 50 cells. Next, DTU was  
796 artificially introduced with the swapping strategy that is described in the bulk simulation study  
797 paragraph of the Methods section of this paper. Finally, we adopted either edgeR or DRIMSeq for  
798 filtering.

799

800 The other two scRNA-seq datasets were generated analogously. For the dataset of Tasic *et al.*<sup>35</sup>, which  
801 was used to construct Figure S8 in the main manuscript, we selected a homogeneous population of  
802 cells by considering only the Lamp5 cells in the anterior lateral motor cortex of mice without any eye  
803 conditions, resulting in a dataset of 897 cells. After introducing DTU, we randomly subsampled 20, 75  
804 or 200 cells from each group. For the dataset of Darmanis *et al.*<sup>25</sup>, which was used to construct Figure  
805 S9, we selected the immune cells that clustered together in tSNE cluster 8 of the original publication,  
806 resulting in a dataset of 248 cells. After introducing DTU, we randomly subsampled 20, 50 or 100 cells  
807 from each group.

808

### 809 Case study DGE analysis

810

811 We perform a DGE analysis on a subset of the Tasic single-cell dataset<sup>35</sup>, i.e. between different the cell  
812 types originating from the ALM and VISp regions of the glutamatergic L5 IT subclass. We use the quasi-  
813 likelihood method of edgeR<sup>32</sup> to model the gene expression profiles and additionally adopt the edgeR  
814 *glmTreat* function to test differential expression against a log<sub>2</sub>-fold change threshold (log<sub>2</sub>-fold  
815 change = 1). Statistical significance was evaluated at the 5% FDR level.

816

### 817 Performance assessment

818

819 We assess the performance of different DTU methods on a bulk simulation dataset with scatterplots  
820 of the true positive rate (TPR) versus the false discovery rate (FDR), according to the following  
821 definitions:

$$822 \quad TPR = \frac{TP}{TP + FN} \quad (9)$$

$$823 \quad FDP = \frac{FP}{FP + TP} \quad (10)$$

$$825 \quad FDR = E[FDP] \quad (11)$$

826 where FN, FP and TP denote the numbers of false negatives, false positives and true positives,  
827 respectively. The FDR-TPR curves are constructed using the Bioconductor R package ICBRA<sup>58</sup>.

830

### 831 Scalability benchmark

832

833 The scalability benchmark was run on subsets of the Chen scRNA-seq dataset<sup>28</sup>, which contains 617  
834 cells in total. For the scalability benchmark with respect to the number of cells in the dataset, we  
835 randomly subsample a certain number of cells (8, 16, 32, 64, 128 or 256 cells per group) from the  
836 dataset (without introducing DTU or selecting specific homogeneous cell populations). Next, we filter  
837 this subsample using the edgeR-based filtering criterion. This was done to remove very lowly abundant  
838 transcripts, which may otherwise cause problems in the parameter estimation procedure. From the  
839 remaining transcripts, we randomly subsampled to a total of 30.000 transcripts before running the  
840 DTU analysis. To allow for a scalability benchmark of BANDITS, which scales poorly to the number of  
841 transcripts (Figure 5B), we also generated a dataset with only 1.000 transcripts (Figure S1).

842

843 For the scalability benchmark with respect to the number of transcripts, we randomly sampled two  
844 groups of 16 cells from the dataset. After applying the edgeR-based filter, we sampled 8 distinct  
845 numbers of transcripts: 1.000, 2.000, 5.000, 10.000, 15.000, 20.000, 25.000, 30.000 and 35.000 prior  
846 to the DTU analysis.

847

848 All scalability benchmarks were run on a single core of a virtual machine with an Intel(R) Xeon(R) CPU  
849 E5-2420 v2 (2.20GHz, Speed: 2200 MHz) processor and 30GB RAM.

### 850 Acknowledgements

851

852 The authors would like to thank Milan Malfait for his suggestions and comments throughout this  
853 project.

### 854 Funding

855

856 Jeroen Gilis, Koen Van den Berge, and Lieven Clement are supported by the Research Foundation  
857 Flanders (FWO), research grant No. G062219N, and Jeroen Gilis is further supported by FWO SB  
858 fellowship No. 3S037119. Koen Van den Berge is a postdoctoral fellow of the Belgian American  
859 Educational Foundation (BAEF) and is supported by the Research Foundation Flanders (FWO), grant  
860 no. 1246220N.

### 861 Competing interests

862

863 The authors declare that they have no competing interests.

## 864 Data and code availability

865

866 satuRn is implemented in an R package that is available at <https://github.com/statOmics/satuRn> and  
867 will be submitted to the Bioconductor project. All the scripts that are required to reproduce the  
868 analyses and figures that are used for this publication can be retrieved from  
869 <https://github.com/statOmics/satuRnPaper>. On this GitHub page, a Zenodo link will provided from  
870 which the raw data and intermediate results of our analyses can be downloaded.

## 871 References

872

- 873 1. Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification.  
874 *Nat. Biotechnol.* **34**, 525–527 (2016).
- 875 2. Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon: fast and bias-aware  
876 quantification of transcript expression using dual-phase inference. *Nat. Methods* **14**, 417–419 (2017).
- 877 3. Wang, E. T. *et al.* Alternative isoform regulation in human tissue transcriptomes. *Nature* **456**, 470–476  
878 (2008).
- 879 4. Pan, Q., Shai, O., Lee, L. J., Frey, B. J. & Blencowe, B. J. Deep surveying of alternative splicing complexity  
880 in the human transcriptome by high-throughput sequencing. *Nat. Genet.* **40**, 1413–1415 (2008).
- 881 5. Trapnell, C. *et al.* Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts  
882 and isoform switching during cell differentiation. *Nat. Biotechnol.* **28**, 511–5 (2010).
- 883 6. Kelemen, O. *et al.* Function of alternative splicing. *Gene* **514**, 1–30 (2013).
- 884 7. Ward, A. J. & Cooper, T. The pathobiology of splicing. *J. Pathol.* **220**, 152–163 (2010).
- 885 8. Wang, G. S. & Cooper, T. A. Splicing in disease: Disruption of the splicing code and the decoding  
886 machinery. *Nat. Rev. Genet.* **8**, 749–761 (2007).
- 887 9. Hallegger, M., Llorian, M. & Smith, C. W. J. Alternative splicing: Global insights. *FEBS J.* **277**, 856–866  
888 (2010).
- 889 10. Oltean, S. & Bates, D. O. Hallmarks of alternative splicing in cancer. *Oncogene* **33**, 5311–5318 (2014).
- 890 11. Picelli, S. *et al.* Full-length RNA-seq from single cells using Smart-seq2. *Nat. Protoc.* **9**, 171–181 (2014).
- 891 12. Hagemann-Jensen, M. *et al.* Single-cell RNA counting at allele and isoform resolution using Smart-seq3.  
892 *Nat. Biotechnol.* **38**, 708–714 (2020).
- 893 13. Katz, Y., Wang, E. T., Airoldi, E. M. & Burge, C. B. Analysis and design of RNA sequencing experiments  
894 for identifying isoform regulation. *Nat. Methods* **7**, 1009–1015 (2010).
- 895 14. Huang, Y. & Sanguinetti, G. BRIE: Transcriptome-wide splicing quantification in single cells. *Genome*  
896 *Biol.* **18**, 1–11 (2017).
- 897 15. Welch, J. D., Hu, Y. & Prins, J. F. Robust detection of alternative splicing in a population of single cells.  
898 *Nucleic Acids Res.* **44**, (2016).
- 899 16. Liu, R., Loraine, A. E. & Dickerson, J. A. Comparisons of computational methods for differential  
900 alternative splicing detection using RNA-seq in plant systems. *BMC Bioinformatics* **15**, 1–16 (2014).
- 901 17. Soneson, C., Matthes, K. L., Nowicka, M., Law, C. W. & Robinson, M. D. Isoform prefiltering improves  
902 performance of count-based methods for analysis of differential transcript usage. *Genome Biol.* **17**, 1–  
903 15 (2016).
- 904 18. Love, M. I. *et al.* Swimming downstream : statistical analysis of differential transcript usage following  
905 Salmon quantification. *F1000Research* 1–61 (2018).
- 906 19. Anders, S., Reyes, A. & Huber, W. Detecting differential usage of exons from RNA-seq data. *Genome*  
907 *Res.* **22**, (2012).
- 908 20. Ruddy, S., Johnson, M. & Purdom, E. Shrinkage of dispersion parameters in the binomial family, with  
909 application to differential exon skipping. *Ann. Appl. Stat.* **10**, 690–725 (2016).
- 910 21. Nowicka, M. & Robinson, M. D. DRIMSeq: a Dirichlet-multinomial framework for multivariate count  
911 outcomes in genomics. *F1000Research* **5**, 1356 (2016).
- 912 22. Chen, Y., Mccarthy, D., Ritchie, M., Robinson, M. & Smyth, G. K. edgeR: differential expression analysis  
913 of digital gene expression data. *User's Guid.* <https://www>, (2019).
- 914 23. Smyth, G. K. Linear Models and Empirical Bayes Methods for Assessing Differential Expression in  
915 Microarray. *Stat. Appl. Genet. Mol. Biol.* **3**, (2006).
- 916 24. Merino, G. A. & Fernandez, E. A. NBSplice: Negative Binomial Models to detect Differential Splicing. R  
917 package. (2019).

- 918 25. Darmanis, S. *et al.* Single-cell RNA-Seq analysis of infiltrating neoplastic cells at the migrating front of  
919 human glioblastoma. *Cell Rep.* **21**, 1399–1410 (2017).
- 920 26. Shalek, A. K. *et al.* Single-cell RNA-seq reveals dynamic paracrine control of cellular variation. *Nature*  
921 **510**, 363–369 (2014).
- 922 27. Petropoulos, S. *et al.* Single-Cell RNA-Seq Reveals Lineage and X Chromosome Dynamics in Human  
923 Preimplantation Embryos. *Cell* **167**, 285 (2016).
- 924 28. Chen, G. *et al.* Single-cell analyses of X Chromosome inactivation dynamics and pluripotency during  
925 differentiation. *Genome Res.* **26**, 1342–1354 (2016).
- 926 29. Tiberi, S. & Robinson, M. D. BANDITS: Bayesian differential splicing accounting for sample-to-sample  
927 variability and mapping uncertainty. *Genome Biol.* **21**, 1–13 (2020).
- 928 30. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to  
929 multiple testing. *J. R. Stat. Soc. Ser. B* **57**, 289–300 (1995).
- 930 31. Van den Berge, K. *et al.* stageR: A general stage-wise method for controlling the gene-level false  
931 discovery rate in differential expression and differential transcript usage, *Genome Biol.* **18**, 1–14  
932 (2017).
- 933 32. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: A Bioconductor package for differential  
934 expression analysis of digital gene expression data. *Bioinformatics* **26**, 139–140 (2009).
- 935 33. Assefa, A. T., Vandesompele, J. & Thas, O. SPsimSeq: Semi-parametric simulation of bulk and single-cell  
936 RNA-sequencing data. *Bioinformatics* **36**, 3276–3278 (2020).
- 937 34. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. *Nat. Genet.* **45**, 580–585 (2013).
- 938 35. Tasic, B. *et al.* Shared and distinct transcriptomic cell types across neocortical areas. *Nature* **563**, 72–78  
939 (2018).
- 940 36. Kang, H. M. *et al.* Multiplexed droplet single-cell RNA-sequencing using natural genetic variation. *Nat.*  
941 *Biotechnol.* **36**, 89–94 (2018).
- 942 37. Durand, S. *et al.* A comparison of visual response properties in the lateral geniculate nucleus and  
943 primary visual cortex of awake and anesthetized mice. *J. Neurosci.* **36**, 12144–12156 (2016).
- 944 38. Cardin, J. A., Kumbhani, R. D., Contreras, D. & Palmer, L. A. Cellular mechanisms of temporal sensitivity  
945 in visual cortex neurons. *J. Neurosci.* **30**, 3652–3662 (2010).
- 946 39. Liu, H., Agam, Y., Madsen, J. R. & Kreiman, G. Timing, Timing, Timing: Fast Decoding of Object  
947 Information from Intracranial Field Potentials in Human Visual Cortex. *Neuron* **62**, 281–290 (2009).
- 948 40. Guo, Z. V. *et al.* Maintenance of persistent activity in a frontal thalamocortical loop. *Nature* **545**, 181–  
949 186 (2017).
- 950 41. Guo, Z. V. *et al.* Flow of cortical activity underlying a tactile decision in mice. *Neuron* **81**, 179–194  
951 (2014).
- 952 42. Carbon, S. *et al.* AmiGO: Online access to ontology and annotation data. *Bioinformatics* **25**, 288–289  
953 (2009).
- 954 43. Yates, A. D. *et al.* Ensembl 2020. *Nucleic Acids Res.* **48**, D682–D688 (2020).
- 955 44. Van Buren, S. *et al.* Compression of quantification uncertainty for scRNA-seq counts. *bioRxiv*  
956 2020.07.06.189639 (2020).
- 957 45. Fujita, K., Iwaki, M. & Yanagida, T. Transcriptional bursting is intrinsically caused by interplay between  
958 RNA polymerases on DNA. *Nat. Commun.* **7**, 1–10 (2016).
- 959 46. Brian, M. & van Oudenaarden, A. Using noise to understand gene regulation. *Science (80-. ).* **336**, 183  
960 (2012).
- 961 47. Najjar, C. F. B. A., Yosef, N. & Lareau, L. F. Coverage-dependent bias creates the appearance of binary  
962 splicing in single cells. *Elife* **9**, 1–23 (2020).
- 963 48. Dobin, A. *et al.* STAR: Ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21 (2013).
- 964 49. Lund, S. P., Nettleton, D., McCarthy, D. J. & Smyth, G. K. Detecting differential expression in RNA-  
965 sequence data using quasi-likelihood with shrunken dispersion estimates. *Stat. Appl. Genet. Mol. Biol.*  
966 **11**, (2012).
- 967 50. Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a  
968 reference genome. *BMC Bioinformatics* **12**, 323 (2011).
- 969 51. McCarthy, D. J., Chen, Y. & Smyth, G. K. Differential expression analysis of multifactor RNA-Seq  
970 experiments with respect to biological variation. *Nucleic Acids Res.* **40**, 4288–4297 (2012).
- 971 52. Efron, B. *Large-Scale Inference: Empirical Bayes Methods for Estimation, Testing, and Prediction.*  
972 *Institute of Mathematical Statistics Monographs. Cambridge University Press* (2010).  
973 doi:10.1111/j.1751-5823.2011.00134\_13.x
- 974 53. Efron, B. Large-scale simultaneous hypothesis testing: The choice of a null hypothesis. *J. Am. Stat.*



975            *Assoc.* **99**, 96–104 (2004).

976    54.    Efron, B., Turnbull, B. B. & Narasimhan, B. Locfdr: Computes Local False Discovery Rates. *R Packag.*  
977            **Version 1.**, <http://CRAN.R-project.org/package=locfdr> (2011).

978    55.    Efron, B. Double exponential families and their use in generalized linear regression. *J. Am. Stat. Assoc.*  
979            **81**, 709–721 (1986).

980    56.    Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: precision weights unlock linear model analysis tools  
981            for RNA-seq read counts. *Genome Biol.* **15**, (2014).

982    57.    Chen, Y., Lun, A. T. L. & Smyth, G. K. From reads to genes to pathways: differential expression analysis  
983            of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood pipeline. *F1000Research* **5**,  
984            1438 (2016).

985    58.    Sonesson, C. & Robinson, M. D. iCOBRA: open, reproducible, standardized and live method  
986            benchmarking. *Nat. Methods* **13**, 283 (2016).

987    59.    Sonesson, C., Love, M. I. & Robinson, M. D. Differential analyses for RNA-seq: transcript-level estimates  
988            improve gene-level inferences. *F1000Research* **4**, 1521 (2016).

989

990

991

992

993

994

995

996

997

998

999


1000

1001

1002


1003

1004 Supplementary Figures  
 1005



1006  
 1007 **Figure S1: Performance and scalability evaluation on a subset of the Love et al. dataset.** To allow for a  
 1008 performance and scalability evaluation of BANDITS, which does not scale to datasets with a large number of  
 1009 transcripts, we here perform a DTU analysis for the *6 versus 6* samples dataset of Love et al. with only 1000  
 1010 transcripts. **Left panel: performance evaluation.** The results are in line with those of Figure 1A. The performance  
 1011 of BANDITS is indicated in pink. **Right panel: Scalability evaluation.** BANDITS scales linearly with respect to the  
 1012 number of cells (or samples) in the dataset. The slope of the linear trend, however, is considerably larger than  
 1013 those of the other DTU methods that scale linearly. Note that the profiles of limma diffsplice, edgeR diffsplice  
 1014 and DoubleExpSeq overlap in this figure.


1015  
 1016  
 1017  
 1018  
 1019  
 1020  
 1021  
 1022  
 1023  
 1024  
 1025  
 1026  
 1027  
 1028  
 1029  
 1030  
 1031  
 1032  
 1033  
 1034  
 1035  
 1036  
 1037  
 1038




1039 **Figure S2: Performance evaluation of satuRn on different subsamples of the simulated bulk RNA-Seq dataset**  
 1040 **by Love et al.** FDR-TPR curves visualize the performance of each method by displaying the sensitivity of the  
 1041 method (TPR) with respect to the false discovery rate (FDR). The three circles on each curve represent working  
 1042 points when the FDR level is set at nominal levels of 1%, 5% and 10%, respectively. The circles are filled if the

1043 empirical FDR is equal or below the imposed FDR threshold. We subsampled two-group comparisons according  
1044 to three different samples sizes; a *3 versus 3*, *6 versus 6* and *10 versus 10* comparison, as denoted in the panel  
1045 titles. The benchmark was performed both on the raw counts (**rows 1 and 2**) or on scaled transcripts-per-million  
1046 (TPM) (**rows 3 and 4**) as imported with the Bioconductor R package tximport<sup>59</sup>. We additionally adopted two  
1047 different filtering strategies: an edgeR-based filtering (**rows 1 and 3**) and a DRIMSeq-based filtering (**rows 2 and**  
1048 **4**). Overall, the performance of satuRn is on par with those of the best tools in the literature, DEXSeq and  
1049 DoubleExpSeq. In addition, satuRn achieves a better control of the FDR on all datasets. For extremely small  
1050 sample size, i.e. the *3 versus 3* comparison, the performance is slightly below that of DEXSeq, and inference does  
1051 become slightly too conservative. Note that, as expected, the performances increase with increasing sample  
1052 size, and a higher performance is achieved with the more stringent DRIMSeq filtering criterion (see Methods),  
1053 which goes at the cost of retaining fewer transcripts for DTU analysis. Finally, we note that the performances  
1054 and FDR control are consistently higher for the scaled TPM data as compared to the raw counts. Note that this  
1055 was only observed for this particular dataset.

1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088



1089




1090  
1091  
1092

**Figure S3: Performance evaluation on different subsamples of the simulated bulk RNA-Seq dataset by Love et al. with a reduced number of transcripts to allow for a comparison with BANDITS. FDR-TPR curves visualize the performance of each method by displaying the sensitivity of the method (TPR) with respect to the false discovery**


1093 rate (FDR). The three circles on each curve represent working points when the FDR level is set at nominal levels  
1094 of 1%, 5% and 10%, respectively. The circles are filled if the empirical FDR is equal or below the imposed FDR  
1095 threshold. We subsampled two-group comparisons according to three different samples sizes; a *3 versus 3*, *6*  
1096 *versus 6* and *10 versus 10* comparison, as denoted on top of the panels. The benchmark was performed both on  
1097 the raw counts (**rows 1 and 2**) or on scaled transcripts-per-million (TPM) (**rows 3 and 4**) as imported with the  
1098 Bioconductor R package tximport<sup>59</sup>. We additionally adopted two different filtering strategies: an edgeR-based  
1099 filtering (**rows 1 and 3**) and a DRIMSeq-based filtering (**rows 2 and 4**). Note that, in contrast to Figure S2, we  
1100 additionally randomly subsampled 1000 genes (~3000-5000 transcripts) after filtering, in order to reduce the  
1101 number of transcripts in the data and thereby allowing for a DTU analysis with BANDITS. In concordance with  
1102 Figure S2, the performance of satuRn is on par with the best tools of the literature with a better control of the  
1103 FDR in general. While the performance of BANDITS is good for the settings for which it was originally developed,  
1104 (i.e., small datasets with a stringent filtering criterium), its performance is reduced in larger, more leniently  
1105 filtered datasets and inference is also overly liberal in these settings. In addition, while all other methods perform  
1106 much better on the scaledTPM data (rows 3 and 4) than on the raw count data (rows 1 and 2), BANDITS has a  
1107 similar performance on both input data types. This can be explained by the fact that BANDITS inherently corrects  
1108 for differences in transcript length, even when raw counts are used as an input.

1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136



1137  
 1138  
 1139  
 1140  
 1141  
 1142  
 1143  
 1144  
 1145  
 1146  
 1147  
 1148  
 1149  
 1150  
 1151  
 1152  
 1153  
 1154  
 1155  
 1156


**Figure S4: Performance evaluation of satuRn on the “Dmelanogaster” simulated bulk RNA-Seq dataset by Van den Berge et al.** FDR-TPR curves visualize the performance of each method by displaying the sensitivity of the method (TPR) with respect to the false discovery rate (FDR). The three circles on each curve represent working points when the FDR level is set at nominal levels of 1%, 5% and 10%, respectively. The circles are filled if the empirical FDR is equal or below the imposed FDR threshold. The benchmark was performed both on the raw counts (**row 1**) and on scaled TPM (**row 2**) as imported with the Bioconductor R package tximport<sup>59</sup>. We additionally adopted two different filtering strategies; an edgeR-based filtering (**column 1**) and a DRIMSeq-based filtering (**column 2**). Overall, the performance of satuRn is on par with those of the best tools in the literature, DEXSeq and DoubleExpSeq. In contrast to the performance evaluation on the dataset by Love et al. (Figures 1A and S2), there is a limited difference in performances based on the data input type (i.e., counts versus scaled TPM), and DRIMSeq also performs well on these datasets.



1158  
 1159  
 1160  
 1161  
 1162  
 1163  
 1164  
 1165  
 1166  
 1167  
 1168  
 1169  
 1170  
 1171  
 1172  
 1173  
 1174









**Figure S5: Performance evaluation of satuRn on the “Hsapiens” simulated bulk RNA-Seq dataset by Van den Berge et al.** FDR-TPR curves visualize the performance of each method by displaying the sensitivity of the method (TPR) with respect to the false discovery rate (FDR). The three circles on each curve represent working points when the FDR level is set at nominal levels of 1%, 5% and 10%, respectively. The circles are filled if the empirical FDR is equal or below the imposed FDR threshold. The benchmark was performed both on the raw counts (**row 1**) and on scaled TPM (**row 2**) as imported with the Bioconductor R package tximport<sup>59</sup>. We additionally adopted two different filtering strategies; an edgeR-based filtering (**column 1**) and a DRIMSeq-based filtering (**column 2**). Overall, the performance of satuRn is on par with those of the best tools in the literature, DEXSeq and DoubleExpSeq. In contrast to the performance evaluation on the dataset by Love et al. (Figures 1A and S2), there is a limited difference in performances based on the data input type (i.e., counts versus scaled TPM), and DRIMSeq also performs well on these datasets.





1176 **Figure S6: Performance evaluation of satuRn on the GTEx bulk RNA-Seq dataset.** FDR-TPR curves visualize the  
1177 performance of each method by displaying the sensitivity (TPR) with respect to the false discovery rate (FDR).  
1178 The three circles on each curve represent working points when the FDR level is set at nominal levels of 1%, 5%  
1179 and 10%, respectively. The circles are filled if the empirical FDR is equal or below the imposed FDR threshold.  
1180 The benchmark was performed both on the raw counts (**rows 1 and 2**) or on scaled transcripts-per-million (TPM)  
1181 (**rows 3 and 4**) as imported with the Bioconductor R package tximport<sup>59</sup>. We additionally adopted two different  
1182 filtering strategies; an edgeR-based filtering (**rows 1 and 3**) and a DRIMSeq-based filtering (**rows 2 and 4**). The  
1183 performance of satuRn is on par with the best tools from the literature, DEXSeq and DoubleExpSeq. In addition,  
1184 satuRn consistently provides a stringent control of the FDR, while DoubleExpSeq becomes more liberal with  
1185 increasing sample sizes. Note that DEXSeq, DRIMSeq and NBSplice were omitted from the largest comparison,  
1186 as these methods do not scale to large datasets (Figure1).


1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230



1231  
1232

1233 **Figure S7: Performance evaluation of satuRn on the real scRNA-Seq dataset by Chen et al.** FDR-TPR curves  
1234 visualize the performance of each method by displaying the sensitivity of the method (TPR) with respect to the  
1235 false discovery rate (FDR). The three circles on each curve represent working points when the FDR level is set at  
1236 nominal levels of 1%, 5% and 10%, respectively. The circles are filled if the empirical FDR is equal or below the  
1237 imposed FDR threshold. The benchmark was performed both on the raw counts (**rows 1 and 2**) or on scaled  
1238 transcripts-per-million (TPM) (**rows 3 and 4**) as imported with the Bioconductor R package tximport<sup>59</sup>. We  
1239 additionally adopted two different filtering strategies; an edgeR-based filtering (**rows 1 and 3**) and a DRIMSeq-  
1240 based filtering (**rows 2 and 4**). The performance of satuRn is at least on par with the best tools from the  
1241 literature. Note that the performance of DEXSeq is clearly lower. In addition, our method consistently controls  
1242 the FDR close to its imposed nominal FDR threshold, while DoubleExpSeq becomes more liberal with increasing  
1243 sample sizes. DEXSeq and DRIMSeq were omitted from the largest comparison (two groups with 50 cells each),  
1244 as these methods do not scale to large datasets (Figure 1). NBSplice was omitted from all comparisons, as it does  
1245 not converge on datasets with many zeros, such as scRNA-Seq datasets.


1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265



1266  
 1267  
 1268  
 1269

1270 **Figure S8: Performance evaluation of satuRn on the real scRNA-Seq dataset by Tasic et al.** FDR-TPR curves  
1271 visualize the performance of each method by displaying the sensitivity of the method (TPR) with respect to the  
1272 false discovery rate (FDR). The three circles on each curve represent working points when the FDR level is set at  
1273 nominal levels of 1%, 5% and 10%, respectively. The circles are filled if the empirical FDR is equal or below the  
1274 imposed FDR threshold. We generated three two-group comparisons of 20, 75 and 200 cells each (left, middle  
1275 and right panel, respectively). The benchmark was performed both on the raw counts (**rows 1 and 2**) or on scaled  
1276 transcripts-per-million (TPM) (**rows 3 and 4**) as imported with the Bioconductor R package tximport<sup>59</sup>. We  
1277 additionally adopted two different filtering strategies; an edgeR-based filtering (**rows 1 and 3**) and a DRIMSeq-  
1278 based filtering (**rows 2 and 4**). Overall, satuRn slightly outperforms DoubleExpSeq, the best tools from the  
1279 literature. Note that the performance of DEXSeq is clearly lower. In addition, our method consistently controls  
1280 the FDR close to its imposed nominal FDR threshold, while DoubleExpSeq becomes more liberal with increasing  
1281 sample sizes. DEXSeq and DRIMSeq were omitted from the largest comparison (two groups with 75 cells and  
1282 200 cells each, respectively), as these methods do not scale to large datasets (Figure 1). NBSplice was omitted  
1283 from all comparisons, as it does not converge on datasets with many zeros, such as scRNA-Seq datasets.

1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318




1319  
 1320  
 1321  
 1322  
 1323  
 1324  
 1325

1326 **Figure S9: Performance evaluation of satuRn on the real scRNA-Seq dataset by Darmanis et al.** FDR-TPR curves  
1327 visualize the performance of each method by displaying the sensitivity of the method (TPR) with respect to the  
1328 false discovery rate (FDR). The three circles on each curve represent working points when the FDR level is set at  
1329 nominal levels of 1%, 5% and 10%, respectively. The circles are filled if the empirical FDR is equal or below the  
1330 imposed FDR threshold. We generated three two-group comparisons of 20, 50 and 100 cells each (left, middle  
1331 and right panel, respectively). The benchmark was performed both on the raw counts (**rows 1 and 2**) or on scaled  
1332 transcripts-per-million (TPM) (**rows 3 and 4**) as imported with the Bioconductor R package tximport<sup>59</sup>. We  
1333 additionally adopted two different filtering strategies; an edgeR-based filtering (**rows 1 and 3**) and a DRIMSeq-  
1334 based filtering (**rows 2 and 4**). Overall, the performance of satuRn is similar to DoubleExpSeq, the best tools  
1335 from the literature. In addition, our method consistently controls the FDR close to its imposed nominal FDR  
1336 threshold, while DoubleExpSeq becomes more liberal with increasing sample sizes. On the dataset with the  
1337 smallest sample size, the FDR control of *satuRn* does become too strict.


1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374





1375  
 1376  
 1377  
 1378  
 1379  
 1380  
 1381  
 1382  
 1383  
 1384  
 1385  
 1386  
 1387  
 1388  
 1389  
 1390  
 1391  
 1392  
 1393  
 1394  
 1395  
 1396  
 1397  
 1398

**Figure S10: The effect of using an empirical null distribution on the false discovery control of satuRn.**  
**Panel A:** Empirical distribution of the satuRn test statistics in one of the bulk transcriptomics benchmark datasets adapted from Love *et al.* The test statistics are z-scores, calculated from satuRn p-values as described in formula 5 (see Methods). As this benchmark dataset is constructed to have 15% DTU transcripts and thus 85% non-DTU or null transcripts, most of these z-scores are expected to follow a standard normal distribution (mean = 0, standard deviation = 1). This is reflected in the maximum likelihood estimates for the mean and variance of the empirical null distribution (mean = -0.002, standard deviation = 1.029). **Panel B:** Corresponding FDP-TPR curve for the bulk transcriptomics benchmark dataset. As the theoretical null distribution and the empirical null distribution are virtually identical, we observe a negligible difference between both strategies, both in terms of performance and FDP control. **Panel C:** Empirical distribution of the satuRn test statistics in one of the single-cell benchmark datasets adapted from Chen *et al.* Again, most of these z-scores are expected to follow a standard normal distribution as this benchmark dataset is also constructed to have 15% DTU transcripts and thus 85% non-DTU or null transcripts. However, the empirical distribution is considerably wider than expected (standard deviation = 1.236). We additionally observe a small shift of the distribution (mean = 0.072). **Panel D:** Corresponding FDP-TPR curve for the single-cell benchmark dataset. While the inference for satuRn is overly liberal when working under the theoretical null, FDP control is restored by adopting the wider empirical null distribution. Note that the performance will only be affected when the empirical null distribution is strongly shifted with respect to the theoretical null (i.e., a large mean in absolute value), which was not the case in this example nor in any other dataset from our analyses.



1400

1401

1402

1403

1404

1405

1406

1407

1408

1409

1410

1411

1412

1413

1414

1415

1416

1417

1418

1419

1420

1421

1422

1423

1424

1425

1426

1427

1428

1429

1430

1431

1432

1433

1434

1435

**Figure S11: Adopting an empirical null distribution to improve FDR control is infeasible for DoubleExpSeq.** Panel A: Distribution of the p-values from a DoubleExpSeq analysis in one of the single-cell benchmark datasets adapted from Chen *et al.* We immediately observe the large spike of p-values equal to 1, which distorts the p-value distribution. In addition, the p-values in the mid-range (e.g., from 0.1 to 0.9), which are expected to be uniformly distributed, are skewed towards smaller values, which underlies the overly liberal results of DoubleExpSeq in our single-cell benchmarks. Panel B: The corresponding empirical distribution of the DoubleExpSeq test statistics. The test statistics are z-scores, calculated from the original DoubleExpSeq p-values as described in formula 5 (see Methods). As all our benchmark datasets are constructed to have 15% DTU transcripts and thus 85% non-DTU or null transcripts, most of these z-scores are expected to follow a standard normal distribution (mean = 0, standard deviation = 1). However, given the pathological distribution of the p-values it is not feasible to properly estimate the empirical null distribution, as also clearly shown by the widely different parameter estimates obtained using the two estimation frameworks implemented in the *locfdr* R package; compare the estimates between MLE (maximum likelihood estimation) and CME (central matching estimation).


1436  
1437  
1438

Comparison	Cell type 1 (ALM)	Cell type 2 (VISP)	DoubleExpSeq FDR	Limma FDR	Limma Empirical FDR
1	Cpa6 Gpr88	Batf3	2142	3602	169
2	Cbln4 Fezf2	Col27a1	644	468	297
3	Cpa6 Gpr88	Col6a1 Fezf2	335	1029	77
4	Gkn1 Pcdh19	Col6a1 Fezf2	1878	2861	58
5	Lypd1 Gpr88	Hsd11b1 Endou	829	1411	249
6	Tnc	Hsd11b1 Endou	4580	4819	341
7	Tmem163 Dmrtb1	Hsd11b1 Endou	3388	5603	176
8	Tmem163 Arhgap25	Whrn Tox2	455	1387	166

1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466

**Figure S12: Number of differentially used transcripts as identified by DoubleExpSeq and limma diffsplice.** The first three columns indicate the comparisons between ALM cell types (column 2) and VISP cell types (column 3), respectively. Column 4 indicates the number of differentially used transcripts as identified by DoubleExpSeq. Column 5 indicates the number of differentially used transcripts as identified by a limma diffsplice analysis with default settings. Column 6 displays the number of differentially used transcripts found by limma diffsplice after correcting for deviations between the theoretical and empirical null distributions.

1467



1468

1469


1470

1471


1472

1473

**Figure S13: Histograms of the p-values from limma diffsplice.** From these histograms, the huge number of DTU transcripts identified by limma diffsplice become apparent. Note that the general tendency of limma diffsplice for smaller p-values is better visible when converting the p-values into z-scores (see Figure S13)




1474 **Figure S14: Empirical distribution of the limma diffsplice test statistics.** The test statistics are z-scores,  
 1475 calculated from limma diffsplice p-values as described in formula 5. Theoretically, these z-scores are  
 1476 expected to follow a standard normal distribution (mean = 0, standard deviation = 1). Here, however,  
 1477 the empirical distributions are considerably wider (standard deviation > 1), as indicated underneath  
 1478 the plots. This indicates that the results returned by limma diffsplice in this case study are overly  
 1479 liberal.



1480

1481 **Figure S15: Histograms of the p-values from DoubleExpSeq.** From these histograms, the huge number  
 1482 of DTU transcripts identified by limma diffsplice become apparent. In addition, we observe a gradual  
 1483 decrease of p-values over the interval  $[0.05 < p < 0.95]$ , with a very large spike of p-values that are  
 1484 exactly 1 in all comparisons or contrasts of interest.



1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493

**Figure S16: Empirical distribution of the test statistics in comparison #6 of the case study with DoubleExpSeq.** The test statistics are z-scores, calculated from DoubleExpSeq p-values as described in formula 5 (see Methods). Theoretically, the bulk of these z-scores are expected to follow a standard normal distribution (mean = 0, standard deviation = 1), i.e., assuming that most transcripts are not differentially used. However, the large spike of p-values equal to 1 (See Figure S14) results spike of z-scores equal to zero, which poses a problem when estimating the empirical null distribution (blue dashed curve).